The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Up to 40% of people with psoriasis have symptoms before they're 16 years old, and 10% get it before they're 10. Children can have mild, moderate, or severe psoriasis. It's a lifelong condition ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

She also mentioned how it connects to her past treatments for psoriasis ... If you could do some hair, you’ll never be broke,” Knowles said. “I told my kids that. My mama told me that.

and plaque psoriasis from head to toe. It lasted for seven months. For those seven months, I didn’t feel like myself. The pain was constant. I couldn’t be present for my kids the way I wanted ...